Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine

Journal of Occupational Medicine and Toxicology

Volumn 9, Issue 1, 2014, Pages

  Findlow, Jamie ^a   Findlow, Helen ^a   Frankland, Sarah ^a   Holland, Ann ^a   Holme, Daniel ^a   Newton, Emma ^a   Southern, Jo ^a   Waight, Pauline ^a   Kaczmarski, Ed ^a   Miller, Elizabeth ^a   Borrow, Ray ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Haemophilus influenzae type b; Laboratory workers; Meningococcal; Occupational immunisation; Tetanus; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCUS TETANUS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DIZZINESS; DRUG SAFETY; FEMALE; FOLLOW UP; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LABORATORY PERSONNEL; MALE; MENINGOCOCCOSIS; NAUSEA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; NOSE OBSTRUCTION; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; POLLEN ALLERGY; SERUM BACTERICIDAL ANTIBODY ASSAY; UNITED KINGDOM; VACCINATION REACTION;

HAEMOPHILUS INFLUENZAE SEROTYPE B;

EID: 84904270983     PISSN: None     EISSN: 17456673     Source Type: Journal    
DOI: 10.1186/1745-6673-9-26     Document Type: Article

References (40)

1. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Ladhani SN, Clin Ther 2012 34 385 399 10.1016/j.clinthera.2011.11.027 22244051
2. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Miller E, Salisbury D, Ramsay M, Vaccine 2001 20 Supplement 1 58 S67 11587814
3. Impact of meningococcal C conjugate vaccine in the UK. Balmer P, Borrow R, Miller E, J Med Microbiol 2002 51 717 722 12358061
4. Risk of laboratory-acquired meningococcal disease. Boutet R, Stuart JM, Kaczmarski EB, Gray SJ, Jones DM, Andrews N, J Hosp Infect 2001 49 282 284 10.1053/jhin.2001.1084 11740877 (Pubitemid 34083083)
5. Health and Safety Executive, Health Services Advisory Committee, Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities London, UK: HSE Books 2003
6. Laboratory-acquired serogroup A meningococcal meningitis. Kessler AT, Stephens DS, Somani J, J Occup Health 2007 49 399 401 10.1539/joh.49.399 17951972
7. Atypical clinical presentation of laboratory-acquired meningococcal disease. Athlin S, Vikerfors T, Fredlund HH, Olcén P, Scand J Infect Dis 2007 2007 39 911 913 (Pubitemid 47470783)
8. A laboratory-acquired infection with Neisseria meningitidis. Bhatti AR, DiNinno VL, Ashton FE, White LA, J Infect 1982 4 247 252 10.1016/S0163-4453(82) 92563-4 6821102 (Pubitemid 12124196)
9. Genotypic and phenotypic modifications of Neisseria meningitidis after an accidental human passage. Omer H, Rose G, Jolley KA, Frapy E, Zahar JR, Maiden MC, Bentley SD, Tinsley CR, Nassif X, Bille E, PLoS One 2011 6 17145 10.1371/journal.pone.0017145 10.1371/journal.pone.0017145 21386889
10. Laboratory-acquired meningococcal disease - United States, 2000. From the Centers for Disease Control and Prevention, JAMA 2002 287 1256 1258 11894852
11. Immunisation against infectious disease-'the green book'. Department of Health, http://immunisation.dh.gov.uk/category/the-green-book/
12. Immune response to meningococcal serogroup C conjugate vaccination in asplenic individuals. Balmer P, Falconer M, McDonald P, Andrews N, Fuller E, Riley C, Kaczmarski E, Borrow R, Infect Immun 2004 72 332 337 10.1128/IAI.72.1.332-337.2004 14688112 (Pubitemid 38018192)
13. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Lal G, Balmer P, Joseph H, Dawson M, Borrow R, Clin Diagn Lab Immunol 2004 11 272 279 15013975 (Pubitemid 38380806)
14. Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for quantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae type b. Pickering JW, Martins TB, Schroder MC, Hill HR, Clin Diagn Lab Immunol 2002 9 872 876 12093688 (Pubitemid 34773893)
15. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Maslanka SE, Gheesling LL, LiButti DE, Donaldson KBJ, Harakeh HS, Dykes JK, Arhin FF, Devi SJN, Frasch CE, Huang JC, Kris-Kuzemenska P, Lemmon RD, Lorange M, Peeters CCAM, Quataert S, Tai JY, Carlone GM, Clin Diag Lab Immunol 1997 4 156 167 (Pubitemid 27130227)
16. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Andrews N, Borrow R, Miller E, Clin Diag Lab Immunol 2003 10 780 786 (Pubitemid 37129487)
17. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. Kayhty H, Peltola H, Karanko V, Makela PH, J Infect Dis 1983 147 1100 10.1093/infdis/147.6.1100 6602191 (Pubitemid 13068358)
18. Borrow R, Balmer P, Roper MH, The Immunological Basis for Immunisation Series. Module 3: Tetanus Geneva, Switzerland: World Health Organization 2007
19. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Borrow R, Andrews N, Goldblatt D, Miller E, Infect Immun 2001 69 1568 1573 10.1128/IAI.69.3.1568-1573.2001 11179328 (Pubitemid 32187610)
20. Human immunity to the meningococcus: I. The role of humoral antibodies. Goldschneider I, Gotschlich EC, Artenstein MS, J Exp Med 1969 129 1307 1326 10.1084/jem.129.6.1307 4977280
21. Human immunity to the meningococcus: II. Development of natural immunity. Goldschneider I, Gotschlich EC, Artenstein MS, J Exp Med 1969 129 1327 1348 10.1084/jem.129.6.1327 4977281
22. Immunity to diphtheria and tetanus in England and Wales. Maple PA, Jones CS, Wall EC, Vyse A, Edmunds WJ, Andrews NJ, Miller E, Vaccine 2000 19 167 173 10.1016/S0264-410X(00)00184-5 10930669 (Pubitemid 30621508)
23. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Ishola DA, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME, Clin Vaccine Immunol 2012 19 1126 1130 10.1128/CVI.05655-11 22647271
24. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Borrow R, Southern J, Andrews N, Peake N, Rahim R, Acuna M, Martin S, Miller E, Kaczmarski E, Vaccine 2001 19 2050 3043
25. Comparison and correlation of Neisseria meningitidis serogroup B immunological assays and human antibody responses following three doses of the 'Norwegian' meningococcal outer membrane vesicle vaccine, MenBvac. Findlow J, Taylor S, Aase A, Horton R, Heyderman R, Southern J, Andrews N, Barchha R, Harrison E, Lowe A, Boxer E, Heaton C, Balmer P, Kaczmarski E, Oster P, Gorringe A, Borrow R, Miller E, Infect Immun 2006 74 4557 4565 10.1128/IAI.00466-06 16861642 (Pubitemid 44157242)
26. Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine. Blanchard-Rohner G, Watt H, Kelly DF, Yu LM, Snape MD, Pollard AJ, Vaccine 2012 30 4153 4159 10.1016/j.vaccine.2012. 04.063 22554466
27. Immunological hyporesponsiveness to group C but not group A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Jokhdar H, Borrow R, Sultan A, Adi M, Riley C, Fuller E, Baxter D, Clin Diagn Lab Immunol 2004 11 83 88 14715549 (Pubitemid 38090656)
28. Safety, immunogenicity and immune memory of a novel meningococcal (groups A, C, Y and W135) polysaccharide diptheria toxoid conjugate vaccine (MCV-4) in health adolescents. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilment G, Reinhardt A, Arch Pediatr Adolesc Med 2005 159 907 913 10.1001/archpedi.159.10.907 16203934 (Pubitemid 41423328)
29. Induction of immunological refractoriness in adults by meningococcal C polysaccharide vaccination. Granoff DM, Gupta RK, Belshe RB, Anderson EL, J Infect Dis 1998 178 870 874 10.1086/515346 9728562 (Pubitemid 28397241)
30. Meningococcal C polysaccharide vaccine induces immunological hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, Hill J, Barker M, Miller E, J Infect Dis 2000 181 761 764 10.1086/315284 10669372 (Pubitemid 30131856)
31. Clinical evaluation of group A and C meningococcal polysaccharide vaccine in infants. Gold R, Lepow ML, Goldschneider I, Draper T, Gotschlich EC, J Clin Invest 1975 56 1536 1547 10.1172/JCI108235 1202084
32. Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig L, Granoff DM, JAMA 1998 280 1685 1689 10.1001/jama.280.19.1685 9832000 (Pubitemid 28532992)
33. Meningococcal group C and W135 immunological hyporesponsiveness in African toddlers. Findlow H, Sow S, Borrow R, Tapia M, Haidara FC, Akinsola AK, Idoko OT, Diallo F, Adegbola R, Tang Y, Parulekar V, Chadha H, Mabey L, Holme D, Townsend K, Chaumont J, LaForce FM, Kulkarni PA, Marchetti E, Viviani S, Hassan-King M, Preziosi MP, Clin Vaccine Immunol 2011 18 1492 1496 10.1128/CVI.05020-11 21752951
34. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Southern J, Deane S, Ashton L, Borrow R, Goldblatt D, Andrews N, Balmer P, Morris R, Kroll JS, Miller E, Clin Diagn Lab Immunol 2004 11 1100 1104 15539513 (Pubitemid 39540851)
35. Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009. Ladhani S, Ramsay M, Flood J, Campbell H, Slack M, Pebody R, Findlow J, Newton E, Wilding M, Warrington R, Crawford H, Min S, Gray K, Martin S, Frankland S, Bokuvha N, Laher G, Borrow R, Euro Surveill 2012 17 46
36. Immunity to tetanus and diphtheria in the UK in 2009. Wagner KS, White JM, Andrews N, Borrow R, Stanford E, Newton E, Pebody RG, Vaccine 2012 30 7111 7117 10.1016/j.vaccine.2012.09.029 23022148
37. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, Martin S, Thornton C, Goldbaltt D, Corbel M, Sesardic D, Cartwright K, Richmond P, Miller E, Infect Immun 2002 70 4946 4954 10.1128/IAI.70.9.4946-4954.2002 12183540
38. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in health Indian adults. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, Elie C, Findlow H, Carloen G, Borrow R, Parulekar V, Plikaytis B, Kulkarni P, Imbault N, LaForce M, Vaccine 2007 25S 101 A107
39. Conjugate meningococcal vaccines development: GSK Biologicals experience. Miller JM, Mesaros N, Van Der Wielen M, Baine Y, Adv Prev Med 2011 10.4061/2011/846756
40. Antibody persistence after serogroup C meningococcal conjugate immunisation of United Kingdom primary-school children in 1999-2000 and responses to a booster: a phase 4 clinical trial. Perrett KP, Winter AP, Kibwana E, Jin C, John TM, Yu LM, Borrow R, Curtis N, Pollard AJ, Clin Infect Dis 2010 50 1601 1610 10.1086/652765 20459323